Abstract: Objective To systematically evaluate efficacy in the application of autologous platelet concentrates (APC) for maxillary sinus floor elevation (MSFE). Methods The databases of PubMed, Embase, Web of Science, Cochrane Library, CNKI, and Wanfang from 1 January 2000 to 30 September 2022, were electronically searched to identify randomized controlled trials (RCTs) involving MSFE employing APC. The Cochrane Tool was employed to assess the risk of bias. Data were analyzed via RevMan 5.4 software. Results In total 16 RCTs were included. Meta-analyses showed that at 6 months after MSFE, APC presented significant advantages in the proportion of new bone formation, grafted materials absorption, vertical bone augmentation, and bone density except for the proportion of connective tissue, bone-to-bone graft contact rate, vertical bone resorption, and implant stability quotient; At 12 months after MFSE, employing APC mixed grafted materials resulted in a significantly better vertical sinus-bone height than employing bone grafted materials alone, but the latter presented a more stable vertical sinus-bone height. Conclusion Limited evidence implied that during a medium-short follow-up period, employing APC mixed bone grafted materials achieves better performance than sole bone grafted materials in terms of the proportion of new bone formation, sinus-bone height, bone density, and materials degradation, thus, no positive efficacy on the proportion of connective tissue, bone-to-bone graft contact rate and the stability of vertical sinus-bone resorption and implant. Further evidence from RCTs with higher homogeneity and longer follow-up period is needed to evaluate its superiority in MSFE.

Key words: Autologous platelet, Growth factors, Maxillary sinus floor elevation, Bone grafting, Randomized controlled trial, Meta-analysis